We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Method Helps Rule Out Heart Valve Infection

By LabMedica International staff writers
Posted on 08 Nov 2017
Print article
Image: A scanning electron photomicrograph of Streptococcus mutans; these bacteria are found in cases of infective endocarditis (Photo courtesy of Dr. David Phillips).
Image: A scanning electron photomicrograph of Streptococcus mutans; these bacteria are found in cases of infective endocarditis (Photo courtesy of Dr. David Phillips).
If a blood sample shows the presence of what is known as alpha-streptococci, there is a risk that the person suffers from infective endocarditis, a heart valve infection and it is an inflammation of the inner tissues of the heart, the endocardium, usually of the valves.

In order to determine whether or not this is the case, the patient must undergo echocardiography, a type of ultrasound examination of the heart, which can be technically difficult to implement and is often unpleasant. Previously, there has been a lack of supporting documentation and evidence to help healthcare professionals determine when such an examination is to be performed on patients.

Clinical scientists at Lund University (Lund, Sweden) developed a risk assessment system, HANDOC, which distinguishes which patients with alpha-streptococci in the blood who are either at high and low risk respectively of suffering from infective endocarditis (IE). The study was based on medical records from 340 adult patients in Skåne University Hospital (Lund, Sweden), whose blood samples showed the presence of alpha-streptococci. In 26 of them, infective endocarditis was confirmed. The investigators mapped the factors that distinguished these patients from those who were not diagnosed with infective endocarditis. Based on the result, an assessment system was constructed.

The investigators found that several factors differed significantly between the patients with IE and those without. Amongst these variables, the presence of heart murmur or valve disease, etiology with the groups of Streptococcus mutans, S. bovis, S. sanguinis or S. anginosus, number of positive blood cultures equal to or greater than two, duration of symptoms of seven days or more, only one species growing in blood cultures, and community acquired infection were chosen to form the HANDOC score. With a cut-off between two and three points, HANDOC had a sensitivity of 100% and specificity of 73% in the first cohort. When tested in the validation cohort, the sensitivity was 100% and the specificity 76%.

Magnus Rasmussen, MD, PhD, an associate professor and senior author of the study, said, “Clinical microbiology has taken strides when it comes to determining bacterial strains, but it's not always clear what this information will mean to the care of the patients. With this assessment system, we have created an easy-to-use tool systematizing how clinicians should treat patients with alpha-streptococci in the blood.” The study was published on October 10, 2017, in the journal Clinical Infectious Diseases.

Related Links:
Lund University
Skåne University Hospital

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.